Back

Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer

Hockings, H.; Lakatos, E.; Huang, W.; Mossner, M.; Khan, M. A.; Metcalf, S.; Nicolini, F.; Smith, K.; Baker, A.-M.; Graham, T.; Lockley, M.

2023-07-25 cancer biology
10.1101/2023.07.21.549688 bioRxiv
Show abstract

Drug resistance results in poor outcomes for most patients with metastatic cancer. Adaptive Therapy (AT) proposes to address this by exploiting presumed fitness costs incurred by drug-resistant cells when drug is absent, and prescribing dose reductions to allow fitter, sensitive cells to re-grow and re- sensitise the tumour. However, empirical evidence for treatment-induced fitness change is lacking. We show that fitness costs in chemotherapy-resistant ovarian cancer cause selective decline and apoptosis of resistant populations in low-resource conditions. Moreover, carboplatin AT caused fluctuations in sensitive/resistant tumour population size in vitro and significantly extended survival of tumour-bearing mice. In sequential blood-derived cell-free DNA and tumour samples obtained longitudinally from ovarian cancer patients during treatment, we inferred resistant cancer cell population size through therapy and observed it correlated strongly with disease burden. These data have enabled us to launch a multicentre, phase 2 randomised controlled trial (ACTOv) to evaluate AT in ovarian cancer.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 8%
18.7%
Similar papers in this journal
2
Cancer Research
● 130 papers in training set
Top 0.1%
13.1%
Similar papers in this journal
3
Nature Cancer
○ 39 papers in training set
Top 0.2%
6.8%
Similar papers in this journal
4
British Journal of Cancer
○ 49 papers in training set
Top 0.1%
6.8%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 21%
5.6%
Similar papers in this journal
50% of probability mass above
6
Science Advances
● 1243 papers in training set
Top 9%
3.5%
7
Communications Biology
○ 993 papers in training set
Top 5%
3.3%
8
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.2%
3.3%
9
Cell Reports Medicine
○ 153 papers in training set
Top 1%
2.8%
10
Cancer Discovery
● 66 papers in training set
Top 0.9%
2.7%
11
npj Precision Oncology
○ 53 papers in training set
Top 0.6%
2.5%
12
Clinical Cancer Research
● 64 papers in training set
Top 0.8%
2.4%
13
Cancers
○ 213 papers in training set
Top 3%
2.1%
14
Cell Reports
○ 1498 papers in training set
Top 19%
1.7%
15
Cancer Cell
○ 42 papers in training set
Top 0.9%
1.3%
16
iScience
○ 1154 papers in training set
Top 23%
1.3%
17
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 32%
1.3%
18
The EMBO Journal
○ 309 papers in training set
Top 4%
1.1%
19
Cancer Research Communications
● 51 papers in training set
Top 1%
1.1%
20
Nature Ecology & Evolution
131 papers in training set
Top 2%
1.1%
21
EMBO Molecular Medicine
○ 95 papers in training set
Top 2%
0.9%
22
Oncogene
○ 85 papers in training set
Top 2%
0.9%
23
PLOS ONE
● 5266 papers in training set
Top 61%
0.6%
24
Scientific Reports
○ 3612 papers in training set
Top 76%
0.6%
25
Developmental Cell
○ 196 papers in training set
Top 4%
0.6%
26
EMBO Reports
○ 263 papers in training set
Top 8%
0.6%
27
Genome Medicine
○ 183 papers in training set
Top 6%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.